MD Anderson/GSK Form Latest Academia/Industry Collaboration, With Oncology Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
University of Texas’ MD Anderson Cancer Center has teamed up with GlaxoSmithKline to develop antibodies that activate OX40. Anderson officials said the deal could be worth as much as $335 million over the course of the transaction.